Liquidia Co. (NASDAQ:LQDA) Stock Holdings Increased by Signaturefd LLC

Signaturefd LLC increased its holdings in Liquidia Co. (NASDAQ:LQDA) by 38,400.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,010 shares of the company’s stock after purchasing an additional 9,984 shares during the quarter. Signaturefd LLC’s holdings in Liquidia were worth $100,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Patient Square Capital LP bought a new stake in shares of Liquidia in the 1st quarter worth approximately $105,942,000. Vanguard Group Inc. raised its holdings in shares of Liquidia by 1.5% in the 1st quarter. Vanguard Group Inc. now owns 2,887,274 shares of the company’s stock worth $42,587,000 after purchasing an additional 43,352 shares in the last quarter. Farallon Capital Management LLC bought a new stake in shares of Liquidia in the 1st quarter worth approximately $30,311,000. Whitefort Capital Management LP raised its holdings in shares of Liquidia by 45.8% in the 1st quarter. Whitefort Capital Management LP now owns 337,607 shares of the company’s stock worth $4,980,000 after purchasing an additional 106,049 shares in the last quarter. Finally, BNP Paribas Financial Markets raised its holdings in shares of Liquidia by 119.4% in the 1st quarter. BNP Paribas Financial Markets now owns 230,248 shares of the company’s stock worth $3,396,000 after purchasing an additional 125,315 shares in the last quarter. 64.54% of the stock is currently owned by institutional investors.

Liquidia Stock Performance

Shares of LQDA opened at $11.03 on Tuesday. The company’s 50 day moving average price is $10.18 and its 200 day moving average price is $11.75. Liquidia Co. has a 52 week low of $6.06 and a 52 week high of $16.99. The company has a market capitalization of $846.99 million, a PE ratio of -7.03 and a beta of 0.22.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.02). The company had revenue of $3.66 million for the quarter, compared to analysts’ expectations of $7.92 million. Liquidia had a negative net margin of 755.46% and a negative return on equity of 183.57%. On average, equities analysts forecast that Liquidia Co. will post -1.69 earnings per share for the current fiscal year.

Insider Buying and Selling at Liquidia

In other Liquidia news, insider Rajeev Saggar sold 2,526 shares of Liquidia stock in a transaction that occurred on Friday, October 18th. The shares were sold at an average price of $11.19, for a total value of $28,265.94. Following the completion of the sale, the insider now directly owns 204,857 shares in the company, valued at $2,292,349.83. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Liquidia news, insider Rajeev Saggar sold 2,526 shares of Liquidia stock in a transaction that occurred on Friday, October 18th. The shares were sold at an average price of $11.19, for a total value of $28,265.94. Following the completion of the sale, the insider now directly owns 204,857 shares in the company, valued at $2,292,349.83. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Michael Kaseta sold 3,892 shares of Liquidia stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $11.11, for a total transaction of $43,240.12. Following the completion of the sale, the chief financial officer now owns 311,076 shares of the company’s stock, valued at $3,456,054.36. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 21,551 shares of company stock worth $236,021 over the last ninety days. 30.10% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on LQDA. Needham & Company LLC reissued a “buy” rating and issued a $25.00 target price on shares of Liquidia in a research report on Monday, August 19th. Scotiabank began coverage on shares of Liquidia in a research report on Wednesday, October 16th. They issued a “sector outperform” rating and a $30.00 target price on the stock. HC Wainwright dropped their target price on shares of Liquidia from $32.00 to $29.00 and set a “buy” rating on the stock in a research report on Tuesday, August 20th. Raymond James raised shares of Liquidia from an “outperform” rating to a “strong-buy” rating in a research report on Monday, August 19th. Finally, BTIG Research dropped their target price on shares of Liquidia from $29.00 to $25.00 and set a “buy” rating on the stock in a research report on Monday, August 19th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $24.67.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).